UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma

Axel Seltsam  Thomas H. Müller
German Red Cross Blood Service NSTOB, Institute Springe, Germany

Keywords
Pathogen inactivation · UVC · Platelet concentrates · Plasma · Blood units

Summary
Besides the current efforts devoted to microbial risk reduction, pathogen inactivation technologies promise reduction of the residual risk of known and emerging infectious agents. A novel pathogen reduction process for platelets, the THERAFLEX UV-Platelets system, has been developed and is under clinical evaluation for its efficacy and safety. In addition, proof of principle has been shown for UVC treatment of plasma units. The pathogen reduction process is based on application of UVC light of a specific wavelength (254 nm) combined with intense agitation of the blood units to ensure a uniform treatment of all blood compartments. Due to the different absorption characteristics of nucleic acids and proteins, UVC irradiation mainly affects the nucleic acid of pathogens and leukocytes while proteins are largely preserved. UVC treatment significantly reduces the infectivity of platelet units contaminated by disease-causing viruses and bacteria. In addition, it inactivates residual white blood cells in the blood components while preserving platelet function and coagulation factors. Since no photoactive compound needs to be added to the blood units, photoreagent-related adverse events are excluded. Because of its simple and rapid procedure without the need to change the established blood component preparation procedures, UVC-based pathogen inactivation could easily be implemented in existing blood banking procedures.

Schlüsselwörter
Pathogeninaktivierung · UVC · Thrombozytenkonzentrate · Plasma · Blutprodukte

Zusammenfassung
Introduction

Improvements in donor screening, good manufacturing practices and viral marker testing have significantly reduced the incidence of transfusion-transmitted infections. However, the blood supply remains under threat from known pathogens which are not assayed in conventional blood screening protocols, from low-titer viruses that escape detection during the window phase of infection, and from novel emerging transfusion-transmissible diseases [1]. A number of different techniques reducing the biological activities of pathogens in blood products have been developed. Current methods use photosensitizers or photoreagents such as methylene blue, amotosalen or riboflavin followed by irradiation with visible or ultraviolet (UV) light [2]. However, photochemicals or their photoproducts may raise the risk of adverse effects such as immune reactions or toxicity. Even after passing through phase III trials, toxicity might not be revealed until large-scale exposure is seen [3].

Recently, a new method for pathogen reduction in blood units was introduced which is solely based on UVC without the use of any photoreactive substance [4–6]. This technology, called THERAFLEX UV-Platelets system, was developed by the Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der DRK-Blutspendedienste e.V.) in cooperation with MacoPharma International GmbH to be used for the inactivation of pathogens and leukocytes in human platelet concentrates. Beside the INTERCEPT (Cerus Corporation, Concord, CA, USA) and the MIRASOL (CaridianBCT Biotechnologies, Lakewood, CO, USA) systems, UVC treatment is the third technology for pathogen reduction of blood units. This review aims to summarize the current status of development of the UVC system. The principle and the mechanism, the toxicological profile and the pathogen inactivation capacity of this technology will be addressed.

Principle and Mechanism of the Technology

Active Principle

It has long been known that UVC is virucidal and microbicidal [7, 8]. A long well established method of UVC irradiation of liquids is used for the treatment of drinking water and waste water. These systems are based on the simple concept of placing an UV lamp centrally in a tube and guiding the liquid to be irradiated past this lamp. However, this method is only effective if the liquid is clear or the irradiation dose can be adjusted. UVC has also been employed to sterilize plasma and plasma derivates [9–11]. It is, however, strongly quenched in turbid or protein-containing solutions. To overcome this problem, blood components must be passed through special devices (e.g. rotating irradiation chambers) to realize homogeneous irradiation by UVC. This is not feasible with single blood units under routine production conditions. A higher radiation dose or, more correctly, a higher intensity would be necessary to increase the penetration depth of the UVC light; however, this would cause damage of the proteins and cells in the blood components.

The active principle used in the THERAFLEX UV-Platelets procedure overcomes this quenching problem by combining UVC irradiation with a strong agitation of the blood bags [4, 6]. Agitation leads to a mixing in the blood bag so that the particles comprising the fluid are transported through the thin photoreactive layer proximate to the surface of the fluid. It is essential for the efficiency of the THERAFLEX UV-Platelets procedure that the blood bags are loosely placed during agitation. In contrast to fixation of blood bags between two quartz plates, the loose placement of the bag allows for an increased mixing rate and wave movement of the bags during agitation. The wave movement causes the formation of areas of layers within the blood unit that become thin enough to be UVC permeable (fig. 1A). Both effects, vigorous and constant mixing and formation of thin layers, may ensure that the entire volume of the blood unit is sufficiently penetrated by UVC light. Experimental data showed that UVC-mediated inactivation of pathogens in unfixed blood bags was agitation speed-dependent and had its maximal efficacy at 100 rotations per minute (rpm) or higher (fig. 1B).

These data suggest that the biological effect of UVC on pathogens inside a blood bag is not simply based on the nominal UVC dose applied but strongly depends on the specific exposure conditions such as the placement, geometry and agitation speed of the treated blood bag. Other parameters such as the cell concentration and the protein content of the irradiated fluid have a great influence on pathogen inactivation efficiency as they critically determine the UVC transparency of the solution to be treated [12]. Thus, only standardized and optimized conditions as realized with the THERAFLEX UV-Platelets procedure and equipment guarantee efficient and reproducible results (table 1).

Mechanism of Action

Short-wave UVC light (wavelength range 200–280 nm) inactivates pathogens mainly by its direct interaction with nucleic acids. This results predominantly in formation of cyclobutane pyrimidine and pyrimidine pyrimidone dimers, which block the elongation of nucleic acid transcripts (fig. 2) [13, 14]. Most of the photoproducts are produced between adjacent pyrimidines. In addition, lesions are generated involving bases located on different DNA strands. Exposure of cells to UVC triggers a global response, which can either counteract the deleterious effects by enabling DNA repair or lead to apoptosis [15, 16]. If the number of hits at viral, bacterial or cellular DNA or RNA exceeds the repair capacity, cells will die or host cells will be unable to allow replication of the respective virus. The problem of treating blood units with UVC is that cells and proteins or other active substances can also be damaged by the ray treatment. There is, however, physically a dose range in which pathogens can be killed without the biologically active
components being damaged. As illustrated in figure 3, the damage to pathogens and to proteins depends on the wavelength of UV radiation. At a wavelength of 254 nm, the viruses, bacteria and parasites are damaged more severely than the proteins. The THERAFLEX UV-Platelets procedure exploits these differences to selectively inactivate pathogens.

**THERAFLEX UV-Platelets Procedure**

Although the proof of principle of UVC treatment of blood units at a clinical scale has been provided for plasma as well as for platelet concentrates [4, 6], only the system for pathogen reduction of platelets has so far been systematically evaluated in preclinical and clinical investigations [17, 18]. The THERAFLEX UV-Platelets process is a simple three-step procedure in which whole blood-derived or apheresis platelets suspended in plasma with additive solution SSP+ (MacoPharma, Tourcoing, France; reference or identical with PAS-IIIM) are first transferred into a UVC-permeable 19 × 38 cm illumination bag. Then, treatment of platelets with UVC is performed 30 min to 24 h after preparation with a UV irradiation device (Macotronic; MacoPharma), whereby illumination of the platelet concentrates is from both sides and the bags are loosely placed on a quartz plate and agitated at 110 rpm with a built-in orbital agitator. The irradiation bag is fixed at its edges by two holders in order to avoid movement of the bag out of the irradiation area while still allowing free movement of the bag walls and the solution inside the bag. An irradiation time of less than 1 min (usually 20–30 s) is equivalent to the desired biologically active UVC dose. The nominal UVC dose applied to the blood bag depends on the UVC per-
riboflavin (vitamin B2) followed by UV irradiation [20]. Photochemicals or their photoproducts may raise the risk of adverse effects such as immune reactions, toxicity or even carcinogenicity. Although these adverse effects are estimated to be rather low [21, 22], it has to be taken into account that studies on pharmacokinetics and side effects for all possible minor photoproducts are difficult to perform. In addition, such studies are limited in assessing the safety margin of a chemical substance that is bound to or incorporated by cells when transfused into a patient. Moreover, only long-term studies will be able to determine the risk, particularly of carcinogenesis, of these photoproducts. In contrast, a pathogen reduction procedure without the need of addition and/or removal of any photoactive reagent would exclude photoreagent-related adverse events. UVC irradiation works without the addition of a photoactive substance or additional new impurities so that conventional approaches to toxicity testing as established for pharmaceuticals are not appropriate for UVC-irradiated human blood units using the THERAFLEX UV-Platelets system.

Although the wavelength of 254 nm used for treatment of blood units is outside the absorption maximum of proteins, UVC light may induce alterations of platelet and plasma proteins. Therefore, preclinical investigations performed with UVC-irradiated platelet concentrates focused on the main safety-relevant end points tolerability and immunogenicity in

Fig. 2. Mechanism of action of UVC light. The pathogen inactivation by UVC is predominantly based on UV absorption by nucleic acids (DNA and RNA). That in turn causes the formation of cyclobutane pyrimidine and pyrimidine pyrimidine dimers, which block the elongation of nucleic acid transcripts. Most of the dimers are formed between adjacent pyrimidines.

**Fig. 2.** Mechanism of action of UVC light.

The pathogen inactivation by UVC is predominantly based on UV absorption by nucleic acids (DNA and RNA). That in turn causes the formation of cyclobutane pyrimidine and pyrimidine pyrimidine dimers, which block the elongation of nucleic acid transcripts. Most of the dimers are formed between adjacent pyrimidines.
Fig. 3. Schematic drawing of the degree of damage to pathogens (viruses, bacteria, parasites), leukocytes and proteins by UV irradiation with different wavelengths. The wavelength ranges of UVB and UVC as well as the specific wavelength of 254 nm used in the Theraflex procedure for pathogen reduction in platelet and plasma units are indicated.

Fig. 4. THERAFLEX UV-Platelets procedure. The THERAFLEX system consists of a UVC illumination device (Macotronic; MacoPharma) and an integral disposable set. The disposable set comprises a plastic illumination bag and a storage bag and provides a single-use, closed, integrated system for pathogen reduction of a platelet unit. The processing steps are described under the section ‘Principle and Mechanism of the Technology’. SCD = sterile connection device.
3 months at –30 °C or less [5]. While the UVC treatment of plasma units is still under development, the treatment-associated losses of factor activities seem to be similar to those found for more established pathogen inactivation procedures already in use for fresh plasma [25–28].

UVC-treated platelets are characterized by a slightly higher metabolic activity (glucose consumption and lactate accumulation) compared to untreated controls. In addition, increased values for parameters such as CD62 expression, Annexin V binding and PAC-1 binding indicate a moderate activation of UVC-treated platelets. The most UVC-sensitive in vitro parameter was identified to be the hypotonic shock reaction (HSR) showing a decrease of 20–30% immediately after UVC irradiation. However, HSR recovers partly during storage of UVC-treated platelets. Thus, in vitro parameters suggest that UVC treatment only moderately influences the functionality of the platelets. Table 2 gives an overview of the quality control data of buffy coat-derived platelet concentrates during storage until day 6 after irradiation.

In vitro Quality

The in vitro quality of plasma proteins and platelets is moderately influenced by UVC treatment. At 1 J/cm² UVC the activities of the clotting factors tested in general were reduced by approximately 10–20% compared to untreated plasma. More sensitive was clotting factor XI whose activity was lowered by approximately 23%. No further reductions were determined after storage of UVC-treated fresh plasma for 3 months at –30 °C or less [5]. While the UVC treatment of plasma units is still under development, the treatment-associated losses of factor activities seem to be similar to those found for more established pathogen inactivation procedures already in use for fresh plasma [25–28].

UVC-treated platelets are characterized by a slightly higher metabolic activity (glucose consumption and lactate accumulation) compared to untreated controls. In addition, increased values for parameters such as CD62 expression, Annexin V binding and PAC-1 binding indicate a moderate activation of UVC-treated platelets. The most UVC-sensitive in vitro parameter was identified to be the hypotonic shock reaction (HSR) showing a decrease of 20–30% immediately after UVC irradiation. However, HSR recovers partly during storage of UVC-treated platelets. Thus, in vitro parameters suggest that UVC treatment only moderately influences the functionality of the platelets. Table 2 gives an overview of the quality control data of buffy coat-derived platelet concentrates during storage until day 6 after irradiation.

In vitro quality data of UVC-irradiated platelets are comparable with the quality reported for other pathogen-inac-
**Fig. 5.** UVC light-induced reduction of disulfide bonds on the platelet surface. **A** The amount of free thiol groups on the platelet surface was measured by the help of maleimide which has a high binding affinity to free thiol groups. Platelets were either left untreated, irradiated with increasing doses of UVC light or treated with dithiothreitol (DTT) as positive control and then incubated with maleimide coupled to the fluorescent dye Alexa633 to label free thiol groups. Binding of the probe was assessed by flow cytometry. Data represent the mean of 4 experiments. **B** To investigate the effect on αIIbβ3 specifically, platelets were incubated with BMCC to biotinylate free thiol groups after the various treatments. Biotinylated proteins were then precipitated with streptavidin agarose beads. The graph depicts the binding of the β3 antibody to the immunoblots of the precipitates as quantified on an imaging system and calculated as percentage of the results of the positive control set as 100%. Data represent the mean of 4 experiments. Arrows indicate the dose of 0.2 J/cm² as used in the THERAFLEX UV-Platelets system.

*Significant differences between negative controls and irradiated samples were detected at a p value of less than 0.05 (paired t-test).

tivated products [29–33]. The relationship between platelet activation in platelet concentrates during storage and platelet function after transfusion and the effect with regard to post-transfusion recovery and survival in recipients is controversial [34–36]. Results on the correlation of other parameters like HSR or lactate with in vivo functionality of platelets are variable [35, 37–39]. Thus, clinical studies will be necessary to determine the functionality and clinical efficacy of UVC-treated platelets. Preliminary results of a radiolabeling study in healthy donors suggest a reduction in recovery and survival.
of autologous UVC-treated platelets, which is in the same range as has been reported for INTERCEPT and MIRASOL platelets [18].

**Proteome**

UVC-induced protein alterations in platelets may be expected for membrane as well as for cytoplasmatic proteins. In a recent biochemical study by Verhaar et al. [40], it was reported that UVC irradiation exerts a direct effect on αIIbβ3 (and other integrins) by modifying extracellular disulfide bonds regulating integrin conformation. This direct activation of platelet αIIbβ3, the fibrinogen receptor, may result in aggregation of stored platelets and influence the hemostatic function of the platelets. It was hypothesized that UVC irradiation gives platelets a ‘sunburn’ which may limit its application for pathogen inactivation of blood products. Indeed, disruption of disulfide bonds of αIIbβ3 by UVC may be responsible for the increased aggregability and PAC-1 binding detectable in UVC-treated platelets. However, the conditions in the study by Verhaar et al. [40], including plasma content, platelet concentration, intensity and time for UVC delivery, type of irradiation vessel and agitation, were completely different from those used in the THERAFLEX UV-Platelets irradiation procedure (table 3). As already mentioned above, the treatment conditions have significant influence on the biological effects of UVC and, thus, on the quality of the product. Although the difference in parameters between the UVC irradiation procedure by Verhaar et al. [40] and the THERAFLEX UV-Platelets system makes it difficult to compare the effective doses, pathogen inactivation data previously published by the same Dutch group strongly suggest that the UVC dose used in the biochemical study was significantly higher than that used in the THERAFLEX UV-Platelets system [12]. Remarkably, for analysis of the disulfide bonds Verhaar et al. [40] washed the platelets before UVC irradiation to remove the plasma although in their previous study [12] they had identified a plasma content of at least 10% to be critical for their system to achieve good pathogen inactivation in combination with good quality. Thus, one would expect that the Theraflex UV procedure using a lower biologically effective dose activates only a minor part of all the αIIbβ3 complexes on the platelet surface.

To test this, we applied the same biological methods as Verhaar et al. [40] to platelets treated with the THERAFLEX system. The amount of free thiol groups on the platelet surface was measured by the help of maleimide which has a high binding affinity to free thiol groups. UVC irradiation caused a dose-dependent increase in free thiol groups on the surface of the platelets, as measured by a fluorescent probe coupled to maleimide (fig. 5A). However, the amount of free thiol groups on platelets was only slightly increased at the standard UVC dose of 0.2 J/cm² used in the THERAFLEX UV-Platelets procedure. To investigate the effect on αIIbβ3 specifically, free thiol groups were labeled with maleimide-coupled biotin after the various treatments, and biotinylated proteins were then precipitated with streptavidin agarose. As shown in figure 5B, after UVC irradiation αIIbβ3 appeared to be labeled with biotin, indicating an increase in free thiol groups by disruption of disulfide bonds in the fibrinogen receptor. This increase showed similar dose dependence as the increase in total free thiol groups on the membrane surface. Again, there was only a moderate increase of free thiol groups on platelets after irradiation with the UVC dose used in the THERAFLEX UV-Platelets system. The laboratory findings observed in UVC-treated platelets are similar to those detected in platelets after UVB irradiation. In contrast to UVC-treated platelet units which are intended to be irradiated just after preparation and then be stored until transfusion, UVB irradiation of platelets was always performed shortly before transfusion. Van Marwijk and colleagues [41] observed that irradiation of platelets with UVB light results in exposure of fibrinogen binding sites and subsequent platelet aggregation. Another group found an increase in the expression of activation in platelets over time and a reduced post-transfusion recovery of UVB-treated platelets in a dose-dependent manner [42]. However, in the Trial to Reduce Alloimmunization to Platelets (TRAP) [43], in which UVB-irradiated platelets were compared with leukocyte-reduced platelets in their ability to prevent alloimmunization and refractoriness to platelet transfusions, it was found that UVB irradiation did not diminish the clinical efficacy of platelet transfusions. The experiences with UVB-treated platelet concentrates demonstrate that it is not possible to predict the in vivo function of UV-treated platelets from laboratory findings. Therefore, future studies in thrombocytopenic patients will have to show whether UVC-treated platelets are clinically effective in maintaining hemostasis.

For a more comprehensive analysis of the impact of UVC on platelet integrity, a proteome study was conducted on the cytosolic proteins [6]. In a pilot study, platelet samples from untreated and UVC-, UVB- or gamma-irradiated human platelet concentrates were analyzed 1 day after treatment. Cytosolic proteins were labeled with different dyes and separated according to their charges by isoelectric focusing and to their sizes in the same polyacrylamide gels in a two-dimen- sional differential in gel electrophoresis (2D-DIGE) to quantitatively assess and characterize changes in the cytosolic platelet proteome induced by the different treatments. The quantitative proteomic study indicated that UVC irradiation shows less effect on the platelet proteome than UVB irradiation and gamma irradiation. Analysis revealed a common set of 92 (out of 793) protein spots affected by all three types of irradiation, whereby specific alterations were most pronounced for gamma irradiation (45 spots), followed by UVB (11 spots) and UVC (only 2 spots). Platelet proteome studies are under way that consider also membrane proteins and are designed to monitor protein alterations in UV- and gamma-irradiated platelet concentrates during storage.
Studies and Current Knowledge about Neoantigens

In addition to the risks described, another type of toxicological effect is the elicitation of an immune response to the UVC-treated platelet product. UVC may induce modification of macromolecules on the platelet surface so as to create a new antigen (neoantigen) that may be detected as foreign by the immune system of the platelet recipient. Similar to the situation in patients alloimmunized against platelet antigens (e.g. HLA, HPA), immune response to UVC-induced neoantigens could result in the formation of antibodies that can bind to the altered platelets and cause them to be cleared from the circulation. Until now, such an immune response has not been reported for MIRASOL or INTERCEPT platelets, for which UV-induced alterations may also be expected. Accordingly, in an animal study we could not detect UVC-induced antibodies against plasma or platelet proteins even after repetitive transfusions of UVC-treated platelets, suggesting that potential alterations in UVC-treated platelets are not highly immunogenic [17]. Clinical studies with pathogen-reduced red blood cells showed that the use of chemical components can result in the formation of antibodies to chemical-dependent neoantigens. Phase III trials in which PEN110, a low molecular weight, cationic ethyleneimide derivative, was used for pathogen reduction of red blood cells, were suspended after patients with an antibody response to PEN110-treated red blood cells had been identified [44]. A similar immunologic problem has been observed with red blood cells treated with the alkylator S-303 [45]. Modification in the S-303 process could reduce but not eliminate this problem [46]. These data suggest that the use of chemical compounds increases the risk for antibody-mediated immune reactions against pathogen-reduced blood cells. The THERAFLEX UV-Platelets procedure, however, has the advantage that it does not need any ingredients to develop its full efficiency. Nevertheless, it will be an important issue in future clinical studies to determine the potential immunogenicity of UVC-treated platelets.

Efficiency of Pathogen Reduction

Bacteria

Investigations on bacteria inactivation in platelet concentrates by UVC included a set of bacteria species with different properties, e.g. Gram-positive and Gram-negative species, aerobes and anaerobes, and spore-forming species. Furthermore, species were chosen that had been associated with transfusion-transmitted bacterial infections: *Staphylococcus epidermidis*, and *Klebsiella pneumoniae* [47, 48]. The UVC procedure was shown to efficiently inactivate the different strains by at least 4 log steps (table 4) [6]. Taking into account the normally very low bacterial titers in contaminated platelet concentrates at the beginning of storage (<1 CFU/ml), reduction rates of >4 log steps may adequately ensure bacterial inactivation [49].

Depending on the respective national guidelines, platelet concentrates can be stored for 4–7 days after preparation before their transfusion. Because the storage conditions of platelet units (at room temperature under continuous agitation) favor the growth of certain bacteria, residual bacteria might grow up again to high titers during subsequent storage, if the pathogen reduction process was incomplete. As pathogen inactivation is only feasible at the manufacturer’s site, a method for routine application should be able to prevent bacterial growth during the storage period. We therefore conducted a study to investigate the sterility of platelet products after UVC treatment and storage for 5–7 days [4]. After spiking with 10–100 CFU/ml, THERAFLEX UV-Platelets treatment was sufficient to sterilize platelet concentrates spiked with a variety of different bacteria strains like *Clostridium perfringens*, *Enterobacter cloacae*, *Escherichia coli*, *K. pneumoniae*, *Propionibacterium acnes*, *Pseudomonas aeruginosa* or *S. epidermidis*. For the spore forming bacterium *Bacillus cereus* the procedure seems to have only limited efficiency. Further experiments will have to show whether these results were due to a contamination of the bacteria preparation with spores known to be significantly less susceptible to UVC than vegetative bacteria [50]. Other pathogen reduction procedures like the INTERCEPT system have also been shown to be incapable of ensuring complete inactivation of *B. cereus*
The efficacy of virus reduction in platelet concentrates was demonstrated using different transfusion-relevant viruses as well as model viruses for common transfusion-relevant viruses. Viruses were chosen in accordance with the current guidelines for virus validation studies [53–55]. Viruses like vesicular stomatitis virus, porcine parovirus (model virus for parovirus B19), encephalomyocarditis virus (model virus for hepatitis A) and Sindbis virus (model virus for hepatitis C) were inactivated with reduction factors of approximately 2–3 and 3.5–4 log steps, respectively. With a reduction factor of only 1 log, HIV proved to be almost resistant to UVC treatment of platelet concentrates [6]. The diploid nature of the virus genome and the HIV-associated reverse transcriptase, which may be unaffected by UVC, may provide the basis for an effective repair mechanism of the virus [56]. However, for HIV and other agents for which screening is performed, pathogen reduction by UVC could eliminate or (in view of the low UVC sensitivity of HIV) at least further reduce the risk for virus transmission during the pre-nucleic acid testing (NAT) window phase and occult infections [57]. In combination with the routine testing for HIV, HCV and HBV, the THERAFLEX UV-Platelets system will therefore significantly improve the viral safety compared to the standard platelet products.

Due to the quenching effect of protein-containing solutions, a higher UVC dose is needed for treatment of plasma units than for plasma-reduced platelet concentrates to achieve a similar degree of virus reduction. However, since the therapeutic efficacy of plasma units relies on proteins which are less sensitive to UVC than blood cells, a higher effective UVC dose could be applied to plasma units without critical loss of functionality. Data on pathogen inactivation of plasma by UVC are preliminary. The efficacy of virus reduction in platelet concentrates was demonstrated using different transfusion-relevant viruses as well as model viruses for common transfusion-relevant viruses. Viruses were chosen in accordance with the current guidelines for virus validation studies [53–55]. Viruses like vesicular stomatitis virus, porcine parovirus (model virus for parovirus B19), encephalomyocarditis virus (model virus for hepatitis A) and Sindbis virus (model virus for hepatitis C) were inactivated with reduction factors of approximately 2–3 and 3.5–4 log steps, respectively. With a reduction factor of only 1 log, HIV proved to be almost resistant to UVC treatment of platelet concentrates [6]. The diploid nature of the virus genome and the HIV-associated reverse transcriptase, which may be unaffected by UVC, may provide the basis for an effective repair mechanism of the virus [56]. However, for HIV and other agents for which screening is performed, pathogen reduction by UVC could eliminate or (in view of the low UVC sensitivity of HIV) at least further reduce the risk for virus transmission during the pre-nucleic acid testing (NAT) window phase and occult infections [57]. In combination with the routine testing for HIV, HCV and HBV, the THERAFLEX UV-Platelets system will therefore significantly improve the viral safety compared to the standard platelet products.

Due to the quenching effect of protein-containing solutions, a higher UVC dose is needed for treatment of plasma units than for plasma-reduced platelet concentrates to achieve a similar degree of virus reduction. However, since the therapeutic efficacy of plasma units relies on proteins which are less sensitive to UVC than blood cells, a higher effective UVC dose could be applied to plasma units without critical loss of functionality. Data on pathogen inactivation of plasma by UVC are preliminary. The UVC irradiation procedure has not been fully validated so far. However, using similar conditions as in the THERAFLEX-UV-Platelets system, all viruses used, with the exception of HIV type 1, were effectively inactivated at a UVC dose of 1 J/cm² [5]. Preliminary data suggest good in vitro quality of plasma proteins after irradiation with a dose of 1 J/cm² [5]. Except for HIV, all viruses used for testing were effectively inactivated by 4–6 log steps at this UVC dose.

**Parasites**

Protozoa like *Plasmodium, Leishmania* or *Trypanosoma* are known to be transmittable by transfusion. Although these pathogens are currently non-endemic in Germany, a certain transfusion risk remains, e.g. by traveling of donors into endemic areas. Currently, the risk of transmission is minimized by exclusion of donors at risk [58, 59]. Preliminary results suggest that UVC treatment has the potential to inactivate *Leishmania infantum and Trypanosoma cruzi* [60]. Future studies will have to confirm that UVC treatment of platelet concentrates adds to the safety of blood products with respect to parasites.

**Leukocytes**

Residual leukocytes remaining in the product after leukodepletion may give rise to various pathological effects in recipients. Apart from the release of a variety of cytokines into the product, the most serious effect of residual leukocytes is the graft-versus-host disease (GvHD) in immunocompromised patients. We performed a series of in vitro experiments to investigate the capacity of UVC to inactivate lymphocytes in platelet concentrates. In mixed lymphocyte cultures, the proliferative responses of alloreactive T cells was inhibited already at low UVC doses. T lymphocytes isolated from UVC-treated platelet concentrates showed clearly reduced proliferative responses after stimulation by the mitogens concanavalin A and phytohemagglutinin. Preliminary investigations showed that the viability of contaminating mononuclear cells (MNCs) was lost throughout the storage period of the platelet concentrates [61]. All these data suggest that residual MNCs in platelet concentrates are effectively inactivated by UVC treatment and that there is a potential for this method to replace gamma-irradiation as state-of-the-art treatment to avoid transfusion-associated GvHD. However, further investigations are currently under way to confirm these results and to quantify the leukocyte inactivation capacity of the THERAFLEX UV-Platelets system.

**Current State of Accreditation in Europe**

The irradiation device (Macotronic UV) and the plastic bag system of the THERAFLEX UV-Platelets system have been CE-marked in 2009. After successful completion of two phase I safety and tolerability studies, approval by the authorities for a phase III clinical trial is expected.

**Acknowledgement**

The authors greatly acknowledge the funding of the ‘Forschungsgemeinschaft der DRK- Blutspendedienste e.V.’ and of MacoPharma for this project.

**Disclosure Statement**

The authors cooperate with MacoPharma in a project to develop the THERAFLEX UV-Platelets system. The authors did not receive any financial support in addition to the project grant and relevant to this manuscript.
References

53 CPMP: Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95 1996
54 CPMP: Note for guidance on plasma-derived medicinal products. CPMP/BWP/269/95 rev3 2001